November 15, 2022
Life Sciences
  • Moderna announced that its new omicron-targeted COVID-19 booster shot performs better against omicron subvariants. New data from a Phase 2-3 clinical trial shows that the vaccine triggered antibody responses against the BA.4 and BA.5 omicron subvariants that were on average 15.1-fold higher. The findings, which are not yet peer-reviewed, are similar to results that Pfizer and BioNTech presented this month about their bivalent coronavirus vaccine booster. (Articles here, here, here, and here)